Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial

Overview of attention for article published in Clinical Cancer Research, November 2022

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 13 X posts from 13 X users, with an upper bound of 42,175 followers.

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 9 additional X posts.